摘要
大数据时代下,新药研发不同环节持续地产生海量的医药相关数据具有较大的潜在价值,然而如何运用大数据的技术使得低价值密度的数据真正产生价值,从真实世界数据到真实世界证据的演变是一个较为成熟的途径。随着监管机构对真实世界证据的逐步认可,未来其在新药研发产业的应用场景将得到进一步扩展,助力新药研发产业的发展。
In the era of big data,m assive a mounts of medical-related data have g reater potential value.However,how to use big data analytical technology to make low-value-density data truly generate value?The evolution from real world d ata to real world evidence is a relatively m ature approach.With the gradual recognition of real-world evidence by regulatory agencies,its application scenarios in the new drug R&D industry will be further expanded in the future,and help develop new drug R&D industry deeply.
作者
刘利利
LIU Lili(Lvyuan District Supervision and Administration Off ice of Changchun Food and Drug Administration,Changchun,Jilin Province,130061 China)
出处
《科技创新导报》
2021年第4期167-169,共3页
Science and Technology Innovation Herald
关键词
真实世界数据
真实世界证据
研发
产业
Real world data(RWD)
Real world evidence(RWE)
Research and development(R&D)
Industry